"""" 0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Astelin Day
`Life Cycle Plan
`November 1, 2002
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX01871176
`
`WOYJCI)jJ!lSl!q!4Xd
`
`- 1-
`U) m ·~
`LL. -
`... ,
`0
`LL. ::I:
`i= ><
`0
`z w
`><
`T""
`:3 <( 1-
`-
`....1
`a..
`a.. 0::
`1-
`
`1
`
`CIP2054
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`CIPLA LTD. EXHIBIT 2031 PAGE 1
`
`CIPLA LTD. EXHIBIT 2031 PAGE 1
`
`
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Astelin Day
`Life Cycle Plan
`November 1, 2002
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX01871176
`
`WOYJCI)jJ!lSl!q!4Xd
`
`- 1-
`U) m ·~
`LL. -
`... ,
`0
`LL. ::I:
`i= ><
`0
`z w
`><
`T""
`:3 <( 1-
`-
`....1
`a..
`a.. 0::
`1-
`
`1
`
`CIP2054
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`CIPLA LTD. EXHIBIT 2031 PAGE 1
`
`CIPLA LTD. EXHIBIT 2031 PAGE 1
`
`
`
`Agenda
`
`1) Review of Detailed
`Proposals and Discussion
`
`45 Min.
`
`2) Breakout Session Instruction
`
`3) Breakout
`What else do we want?
`Supply source/packaging?
`Trademarks/specifications?
`Studies directed specifically
`toward target messages?
`
`60 Min.
`
`4) Reconvene and Report Back
`
`30 Min.
`
`5) Prioritize and Next Steps
`
`30 Min.
`
`N
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-a.
`
`R. Spivey/
`D. Fink
`
`D. Fink
`
`All
`
`D. Fink/
`R. Spivey
`
`D. Fink/
`R. Spivey
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`2
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871177
`
`2
`
`CIPLA LTD. EXHIBIT 2031 PAGE 2
`
`CIPLA LTD. EXHIBIT 2031 PAGE 2
`
`
`
`M
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`AstelirP
`
`Projects
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`3
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871178
`
`3
`
`CIPLA LTD. EXHIBIT 2031 PAGE 3
`
`CIPLA LTD. EXHIBIT 2031 PAGE 3
`
`
`
`-.::t
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Packaging Configuration Projects
`
`• Pediatric packaging
`
`• V-Bottom bottle/ cap configuration - trade
`(30.0 ml)
`
`• V-Bottom bottle/pump configuration- trade
`(30.0 ml)
`
`• V-Bottom bottle- sample (5 ml)
`
`• Calmar- Albert pump
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`4
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871179
`
`4
`
`CIPLA LTD. EXHIBIT 2031 PAGE 4
`
`CIPLA LTD. EXHIBIT 2031 PAGE 4
`
`
`
`II)
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Pediatric Packaging
`
`• Single 17 ml flat-bottom bottle
`
`• Current VP3 Valois pump
`
`• Straight-forward; high probability of success
`
`• Timing influenced by whether ''value added''
`materials are included
`
`• Cost is minimal
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`5
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871180
`
`5
`
`CIPLA LTD. EXHIBIT 2031 PAGE 5
`
`CIPLA LTD. EXHIBIT 2031 PAGE 5
`
`
`
`CD
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`V-Bottom Bottle/Cap Configuration- Trade
`[~l!IJJ~l
`
`• Back-up strategy for ''pump on'' plan for new
`V-bottom bottle
`
`• High likelihood of success
`
`• Requires development of data, submission,
`and approval by FDA
`
`• Available in 18 - 24 months
`
`• Cost is relatively small
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`6
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871181
`
`6
`
`CIPLA LTD. EXHIBIT 2031 PAGE 6
`
`CIPLA LTD. EXHIBIT 2031 PAGE 6
`
`
`
`.......
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`V-Bottom Bottle/Pump Configuration -
`Trade (.lflm~l
`
`• Current, planned configuration for new V(cid:173)
`bottom bottle
`
`• Requires additional engineering efforts to
`periect pump placement
`
`• In addition, particulates may be an issue
`
`• Available in 6 - 9 months
`
`• Cost is estimated at $350 - 400k
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`7
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871182
`
`7
`
`CIPLA LTD. EXHIBIT 2031 PAGE 7
`
`CIPLA LTD. EXHIBIT 2031 PAGE 7
`
`
`
`00
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`V-Bottom Bottle -Sample (5 mL}
`
`• Already approved by FDA
`
`• Issues similar to 30 ml V-bottom bottle
`
`• Available in 6 - 9 months
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`8
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871183
`
`8
`
`CIPLA LTD. EXHIBIT 2031 PAGE 8
`
`CIPLA LTD. EXHIBIT 2031 PAGE 8
`
`
`
`0')
`0
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Colman- Albert Pump
`
`• Qualification of back-up pump supplier
`
`• Moderate likelihood of success
`
`• Available in 18 - 24 months
`
`• Cost is approximately $2.5 million
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`9
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871184
`
`9
`
`CIPLA LTD. EXHIBIT 2031 PAGE 9
`
`CIPLA LTD. EXHIBIT 2031 PAGE 9
`
`
`
`0
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Formulations Projects
`
`• Astelin/ steroid combination
`
`• Taste masking- meet current
`specifications
`
`• New optimized formulation
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`10
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871185
`
`10
`
`CIPLA LTD. EXHIBIT 2031 PAGE 10
`
`CIPLA LTD. EXHIBIT 2031 PAGE 10
`
`
`
`""""
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Astelin/Steroid Combination
`
`• High degree of technical difficulty
`
`• Need to reconcile combination of
`sol uti on I suspension
`
`• Dosing differences
`
`• 4- 5 years to develop; $75 million
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`11
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871186
`
`11
`
`CIPLA LTD. EXHIBIT 2031 PAGE 11
`
`CIPLA LTD. EXHIBIT 2031 PAGE 11
`
`
`
`N
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Taste Masking- Meet Current
`
`• Multiple attempts made but all altered
`specifications
`
`• No feasibility to make modifications
`without extensive product
`characterization and some clinical trials
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`12
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871187
`
`12
`
`CIPLA LTD. EXHIBIT 2031 PAGE 12
`
`CIPLA LTD. EXHIBIT 2031 PAGE 12
`
`
`
`M
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`New Optimized Formulation
`
`• To improve taste and optimize dosing
`
`• Need to assemble taste panels to
`determine success
`
`• 3-4 years in development
`
`• Would likely cost $4.5 million
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`13
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871188
`
`13
`
`CIPLA LTD. EXHIBIT 2031 PAGE 13
`
`CIPLA LTD. EXHIBIT 2031 PAGE 13
`
`
`
`-.::t
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Clinical Programs
`
`• One spray per nostril bid (supplemental NDA)
`
`• Perennial allergic rhinitis (supplemental NDA)
`
`• Protocol 415 (follow-on to Protocol 414
`Claritin failure trial)
`
`• SAR and asthma
`
`• Somnolence/ cognitive function studies
`
`• Nasal polyps (pilot study)
`
`• Pediatric labeling (children 2 to 4 years of age)
`
`• Non-allergic asthma (NIH study)
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`14
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871189
`
`14
`
`CIPLA LTD. EXHIBIT 2031 PAGE 14
`
`CIPLA LTD. EXHIBIT 2031 PAGE 14
`
`
`
`II)
`
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`One Spray BID
`
`• New dosage regimen (current formulation)
`
`• At least 2 trials
`
`• Cost is approximately $2.5 - $3 million
`
`• New labeling by 2005
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`15
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871190
`
`15
`
`CIPLA LTD. EXHIBIT 2031 PAGE 15
`
`CIPLA LTD. EXHIBIT 2031 PAGE 15
`
`
`
`CD
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Perennial Allergic Rhinitis
`
`• New indication
`
`• High feasibility; moderate to high
`likelihood of success
`
`• Available mid-2005
`
`• Cost is approximately $3 million
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`16
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871191
`
`16
`
`CIPLA LTD. EXHIBIT 2031 PAGE 16
`
`CIPLA LTD. EXHIBIT 2031 PAGE 16
`
`
`
`.......
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Follow-up to 414
`
`• Follow-up to Claritin failure trial
`
`• Could duplicate study 414 or study different
`antihistamine (Allergen or Zyrtec)
`
`• Study completed mid-2003
`
`• Cost is approximately $2 million
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`17
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871192
`
`17
`
`CIPLA LTD. EXHIBIT 2031 PAGE 17
`
`CIPLA LTD. EXHIBIT 2031 PAGE 17
`
`
`
`()()
`
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`SAR and Asthma
`
`• Effect of Astelin on SAR symptoms in
`patients with both asthma and SAR.
`Evaluate if any impact on asthma
`symptoms •
`
`• Low-to-moderate likelihood of success
`
`• Cost is approximately $1 million
`
`• Publication available in 2004
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`18
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871193
`
`18
`
`CIPLA LTD. EXHIBIT 2031 PAGE 18
`
`CIPLA LTD. EXHIBIT 2031 PAGE 18
`
`
`
`0')
`
`"""" 0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Somnolence/ Cognitive Function Studies
`
`• Provide data for PI in Clinical Pharmacology
`section on sleep latency and/or cognitive
`function
`
`• Two studies, total of $600K
`
`• Submission in 2004, label change by end of
`2004
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`19
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871194
`
`19
`
`CIPLA LTD. EXHIBIT 2031 PAGE 19
`
`CIPLA LTD. EXHIBIT 2031 PAGE 19
`
`
`
`0
`N
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Nasal Polyps (Pilot Study)
`
`• Evaluate effect of Astelin on nasal polyps
`
`• Depends on anti-inflammatory effect
`
`• Cost is approximately $850K
`
`• Outcome is publication
`
`• Low likelihood of success
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`20
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871195
`
`20
`
`CIPLA LTD. EXHIBIT 2031 PAGE 20
`
`CIPLA LTD. EXHIBIT 2031 PAGE 20
`
`
`
`"""" N
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Pediatric Labeling (2- 4 years)
`
`• Formally requested by FDA
`
`• Lengthy enrollment process (over 2 allergy
`seasons)
`
`• Cost is approximately $700K
`
`• Could result in 6 months of exclusivity
`
`• Submit to FDA by 2005
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`21
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871196
`
`21
`
`CIPLA LTD. EXHIBIT 2031 PAGE 21
`
`CIPLA LTD. EXHIBIT 2031 PAGE 21
`
`
`
`N
`N
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Non-allergic Asthma (NIH funded)
`
`• Investigator is Dr. Jonathan Bernstein
`
`• Low-to-moderate likelihood of success
`
`• Drug supplier only (already committed)
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`22
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871197
`
`22
`
`CIPLA LTD. EXHIBIT 2031 PAGE 22
`
`CIPLA LTD. EXHIBIT 2031 PAGE 22
`
`
`
`M
`N
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Preclinical Program
`
`• Otitis media (animal model)
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`23
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871198
`
`23
`
`CIPLA LTD. EXHIBIT 2031 PAGE 23
`
`CIPLA LTD. EXHIBIT 2031 PAGE 23
`
`
`
`-.::t
`N
`0
`0
`0
`I
`II)
`0
`0
`
`"""" >< I-
`
`C..
`
`Otitis Media
`
`• Effects of antihistamine on middle ear
`effusion
`
`• Study to be conducted in rats
`
`• Publication
`
`• Drug supplier committed
`
`~neci-IJol~le
`
`/:::=::::,,::;·_;::;:·-;::,;:·~:=:.--:~· ·=· ·:·::·~· ~· :~ /:·~ .: i·=·: 'tx A::;::::~::t:·:t:~:;::;::-=··
`
`24
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`September 2fi
`/01'1
`
`MEDA_APTX01871199
`
`24
`
`CIPLA LTD. EXHIBIT 2031 PAGE 24
`
`CIPLA LTD. EXHIBIT 2031 PAGE 24
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
